Brokers Set Expectations for Inari Medical FY2026 Earnings

Inari Medical, Inc. (NASDAQ:NARI) – Investment analysts at Leerink Partnrs reduced their FY2026 EPS estimates for Inari Medical in a research report issued to clients and investors on Monday, October 28th. Leerink Partnrs analyst M. Kratky now anticipates that the company will earn $0.19 per share for the year, down from their previous estimate of $0.21. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Inari Medical’s current full-year earnings is ($0.75) per share. Leerink Partnrs also issued estimates for Inari Medical’s FY2027 earnings at $0.56 EPS and FY2028 earnings at $1.00 EPS.

Inari Medical (NASDAQ:NARI) last issued its earnings results on Tuesday, July 30th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.25). Inari Medical had a negative net margin of 10.42% and a negative return on equity of 7.51%. The firm had revenue of $145.82 million during the quarter, compared to analyst estimates of $143.96 million.

A number of other research analysts have also weighed in on NARI. Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a report on Tuesday. Canaccord Genuity Group upped their price objective on shares of Inari Medical from $71.00 to $74.00 and gave the company a “buy” rating in a report on Tuesday. William Blair assumed coverage on shares of Inari Medical in a research report on Thursday, July 25th. They issued an “outperform” rating on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Inari Medical in a report on Friday, August 9th. They set a “buy” rating and a $68.00 target price for the company. Finally, Piper Sandler increased their price target on shares of Inari Medical from $50.00 to $52.00 and gave the company a “neutral” rating in a report on Tuesday. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $58.89.

Inari Medical Stock Down 4.2 %

Shares of NASDAQ NARI opened at $47.10 on Wednesday. The business’s 50 day moving average price is $43.51 and its two-hundred day moving average price is $45.96. The company has a market cap of $2.74 billion, a PE ratio of -37.25 and a beta of 1.00. Inari Medical has a twelve month low of $36.73 and a twelve month high of $67.13.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. increased its stake in shares of Inari Medical by 113.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company’s stock valued at $71,324,000 after purchasing an additional 786,691 shares during the last quarter. Armistice Capital LLC boosted its stake in Inari Medical by 353.1% in the second quarter. Armistice Capital LLC now owns 1,009,252 shares of the company’s stock valued at $48,595,000 after buying an additional 786,501 shares in the last quarter. Vanguard Group Inc. grew its position in Inari Medical by 11.1% in the first quarter. Vanguard Group Inc. now owns 5,599,854 shares of the company’s stock valued at $268,681,000 after acquiring an additional 561,562 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Inari Medical by 1,219.9% during the second quarter. The Manufacturers Life Insurance Company now owns 394,901 shares of the company’s stock worth $19,014,000 after acquiring an additional 364,983 shares in the last quarter. Finally, First Light Asset Management LLC lifted its holdings in shares of Inari Medical by 120.8% in the second quarter. First Light Asset Management LLC now owns 472,384 shares of the company’s stock worth $22,745,000 after acquiring an additional 258,444 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Inari Medical

In related news, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total value of $1,800,800.00. Following the completion of the sale, the director now directly owns 601,233 shares in the company, valued at approximately $27,067,509.66. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total value of $1,800,800.00. Following the completion of the transaction, the director now owns 601,233 shares of the company’s stock, valued at $27,067,509.66. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Mitch C. Hill sold 5,000 shares of the stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $47.99, for a total transaction of $239,950.00. Following the sale, the chief financial officer now owns 179,600 shares in the company, valued at $8,619,004. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 88,000 shares of company stock valued at $4,009,340. 10.60% of the stock is currently owned by company insiders.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.